BerGenBio rang the bell at the Oslo Stock Exchange

All smiles when Richard Godfrey, CEO of BerGenBio, rang the opening bell at the Oslo Stock Exchange this morning. BerGenBio is the first company out of the BTO portfolio that will trade its shares on the stock market.

BerGenBio announced the successful completion of its IPO (initial public offering) on 6th of April.  Friday 7th April was the first day of trading for the company’s shares on the Oslo Stock Exchange.

We are delighted with the positive support BerGenBio has received from investors in Norway and internationally. This new funding will enable the Company to develop first in class medicines to treat aggressive cancers that have become immune-evasive, drug-resistant and metastatic“, stated Richard Godfrey, CEO of BerGenBio, in a press release after the completion of the IPO.

The shares in the initial IPO where priced at NOK 25 per share. The price implied a market capitalisation of BerGenBio after the IPO of NOK 1,244 million.

Potential milestone for start-ups in Bergen

BerGenBio was established by BTO, Unifob and researchers from the University of Bergen ten years ago. Today’s event on the Oslo Stock Exchange is of great importance to Bergen Teknologioverføring and the research institutions we serve.

– BerGenBio is a flagship among all companies that have emerged from the research institutions in Bergen. In 20 years, this day might stand as a milestone in the history of the start-up companies in our city, says Anders Haugland, Managing director of BTO.

Developing a pipeline of first-in-class drug candidates

Pills on a tray

This is how the pill with cancer medicine look like. This is now being tested on a number of patients. Photo: Kjetil Myhren-Berge

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates to treat multiple aggressive cancers. BerGenBio has pioneered the research and understanding of the central role of Axl kinase in a broad range of aggressive cancers that spread, avoid the immune system and are resistant to existing drugs. Tumours with these characteristics are the cause of the majority of cancer deaths.

BerGenBio is developing a number of Axl kinase inhibitors, which represents a novel approach to address the key mechanisms leading to tumours becoming malignant and aggressive. This approach presents BerGenBio with an opportunity to create new therapeutic options for cancer patients.

BerGenBio’s most advanced drug development program, BGB324, is a highly selective, orally bioavailable small molecule Axl inhibitor, currently in Phase II clinical development. It is the only selective Axl inhibitor in clinical development. BGB324 has already delivered encouraging clinical data.

Related posts

BerGenBio logo
09.03.2017
BerGenBio applies for a listing on Oslo Børs

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates to treat multiple aggressive cancers. BerGenBio has pioneered the research and understanding of the central role of Axl kinase in a broad range of aggressive cancers that spread, avoid the immune system and are resistant to existing drugs. Tumours with these characteristics are the cause…

Read more
Featured image for the post The Prime Minister mentions BerGenBio in her New Year’s Speech
05.01.2017
The Prime Minister mentions BerGenBio in her New Year’s Speech

The unemployment rate in Norway has increased the latest few years, mainly because of the decreasing oil price. In order to face this challenge, the Prime Minister encouraged to support entrepreneurs and people taking personal initiative. Politicians can facilitate companies and individuals creating new jobs, but in order to actually create them Norway is dependent on the initiative from private…

Read more
Picture of Richard Godfrey
18.03.2016
BerGenBio secures 212 million NOK capital raise

BerGenBio will use the proceeds and its existing cash balance to progress the development of the Company’s pipeline of innovative cancer therapeutics, in particular its lead asset BGB324, a first-in-class Axl kinase inhibitor. BGB324 is currently being evaluated in a Phase 1b trial in patients with acute myeloid leukaemia (AML); and in a Phase 1b trial in patients with Stage…

Read more
Featured image for the post BerGenBio won nordic innovation award
10.09.2015
BerGenBio won nordic innovation award

Richard Godfrey, CEO of BerGenBio, received the award at the Nordic Life Science Days in Stockholm. – I am honoured to receive this award on behalf of the company in recognition of the potential our innovative cancer drugs hold for patients, says Richard Godfrey to bergento.no. Nordic Stars Awards were introduced in 2013 in special recognition of life science companies…

Read more
Featured image for the post BerGenBio appoints non-executive directors
02.09.2015
BerGenBio appoints non-executive directors

Dr Stener Kvinnsland has more than 30 years of experience in oncology. He is Chair of Board, Oslo University Hospital. Among Dr Kvinnsland’s previous roles, he was Chief Executive Officer of the Bergen Hospital Trust (Helse Bergen), Head of the Department of Oncology and Medical Physics at Haukeland University Hospital, Professor of Medicine (Oncology) at the University of Bergen and…

Read more
Featured image for the post The biodream in Bergen – BerGenBio against the current in midst of financial crisis
18.01.2012
The biodream in Bergen - BerGenBio against the current in midst of financial crisis

The study concludes that the high-tech start-up companies are among the first to perish in the midst of a global financial crisis. The small biotech company BerGenBio AS, a BTO startup company, is an example of the oposite. Before Christmas 2011, the company accomplished to raise substantial funding from investors, 52 mill NOK in equity capital.Read complete article here BT…

Read more